Closed Loop Medicine Ltd., a TechBio company that develops combination prescription drug plus software therapy products that enable personalized dose optimization, appointed Kate Woolland as chief operating officer. Woolland joins CEO, Hakim Yadi, on the executive team to guide organizational and operational delivery of the Company’s lead programs, products and commercial partnerships.

Woolland’s appointment follows Closed Loop Medicine’s recent announcement of a co-development partnership deal with Pharmanovia, a global lifecycle management healthcare company, for drug plus software product solutions for the treatment of hypertension.

In a statement, the company said that bringing extensive strategic business experience, including over 13 years in healthcare, Woolland strengthens the executive team and supports the Company as it continues to scale commercial development. As COO, she will play a pivotal role in leading collaboration across the multi-disciplinary team whilst working closely with current and future commercial partners to drive delivery of Closed Loop Medicine’s products to market.

In her previous role, Kate was Chief Delivery Officer at ieso Digital Health, where she led product, design, clinical trial operations, commercial, regulatory and program management functions. During that time, Kate secured ieso’s first commercial partnerships and launched its first medical device. 

Kate Woolland, COO of Closed Loop Medicine, said: “I am thrilled to join the Closed Loop Medicine team at such an exciting stage. Leveraging the capabilities of our incredible technologies to revolutionize the dosing of medicines has the potential to help patients and healthcare professionals better manage health conditions, improve quality of life and healt h outcomes for millions of people. I am delighted to have the opportunity to play a part in such ground-breaking work.”  

Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, said: “As chief operating officer, Kate brings a wealth of experience in optimizing and improving health systems and helping scale next generation digitally delivered health services from her time at ieso. We are on a mission to provide the right dose of medicine to patients and are excited to have Kate join us on this journey, helping build and develop our team dedicated to dose optimization and combination products.”